Enhertu

News

ESMO: Trodelvy's overall survival benefit revealed

Prospects for Gilead Sciences' Trodelvy in hormone receptor-positive, HER2-negative metastatic breast cancer continue to improve as data from the TROPiCs-02 trial strengthen, but the jury i

News

Enhertu role in breast cancer confirmed, as Daiichi wins Sea...

AstraZeneca and Daiichi Sankyo have the confirmatory trial data they were hoping for with Enhertu as a treatment for advanced, HER2-positive breast cancer in previously-treated patients.

News

AZ gets FDA nod for Enhertu in first HER2-low cancer

The FDA has approved AstraZeneca and Daiichi Sankyo's Enhertu as the first targeted therapy for HER2-low breast cancer, a new category of the disease that was once lumped under the HER2-neg

News

AstraZeneca raises 2022 guidance, names Demaré as non-exec c...

AstraZeneca chief executive Pascal Soriot said this morning that strong revenue increases in 2022 – fuelled by its COVID-19 antibody Evusheld and oncology drugs – have allowed the company t

News

AstraZeneca Amenities Building - Mississauga - Sept 2005
Non exclusive, unlimited time license for print & web to WZMH Architects

FDA verdict on Enhertu in HER2-low breast cancer due before ...

AstraZeneca and Daiichi Sankyo will hear back from the FDA before the end of 2022 on their license application for Enhertu in HER2-low breast cancer – an indication which could drive the dr

News

Court won't raise Seagen damages award in Enhertu patent dis...

A Texas court has confirmed the $41.8 million damages awarded to Seagen in its patent dispute with Daiichi Sankyo over beast cancer drug Enhertu, but declined to raise the sum despite concl

ESMO: Trodelvy's overall survival benefit revealed

Enhertu role in breast cancer confirmed, as Daiichi wins Sea...

AZ gets FDA nod for Enhertu in first HER2-low cancer

AstraZeneca raises 2022 guidance, names Demaré as non-exec c...

FDA verdict on Enhertu in HER2-low breast cancer due before ...

Court won't raise Seagen damages award in Enhertu patent dis...

Jazz builds in epilepsy with $1.3bn Actio acquisition

Discover a new era of healthcare panel engagement: Grounded ...

Enhertu

Editor's Picks